What is Axion BioSystems?
Founded in 2007 and headquartered in Atlanta, GA, Axion BioSystems specializes in developing cutting-edge technologies designed to address complex challenges in understanding human heart and brain activity. The company's solutions are critical for researchers and clinicians seeking to advance neurological and cardiac studies. Axion BioSystems operates within the rapidly evolving life sciences and medical technology landscape, contributing to advancements in diagnostics and therapeutic research through its proprietary platforms.
How much funding has Axion BioSystems raised?
Axion BioSystems has raised a total of $7.6M across 3 funding rounds:
Private Equity
$6.3M
Debt
$350K
Debt
$963K
Private Equity (2016): $6.3M with participation from GRA Venture Fund
Debt (2020): $350K led by PPP
Debt (2021): $963K supported by PPP
Key Investors in Axion BioSystems
GRA Venture Fund
GRA Venture Fund is a venture capital firm focused on supporting university research and entrepreneurship, particularly in Georgia. They invest in startups and technologies emerging from academic research, aiming to foster innovation and economic growth in sectors like life sciences and technology.
What's next for Axion BioSystems?
The recent strategic investment signals a pivotal phase for Axion BioSystems, likely enabling the company to scale its operations, expand its research and development capabilities, and potentially broaden its market reach. Given the enterprise-level nature of its funding, Axion BioSystems is poised for significant expansion, possibly exploring new applications for its technology or enhancing its existing product lines. This capital will be instrumental in solidifying its position as a leader in biosensing technologies for cardiac and neurological applications, driving innovation and further contributing to advancements in human health.
See full Axion BioSystems company page
